enGene (NASDAQ:ENGN - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.
Other research analysts have also issued research reports about the company. Morgan Stanley dropped their target price on enGene from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Friday, September 12th. HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of enGene in a report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $19.50.
Read Our Latest Analysis on enGene
enGene Stock Up 5.6%
Shares of ENGN stock traded up $0.47 during trading hours on Tuesday, reaching $8.76. The company had a trading volume of 54,518 shares, compared to its average volume of 129,422. enGene has a 12 month low of $2.65 and a 12 month high of $11.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The business has a fifty day simple moving average of $5.58 and a 200-day simple moving average of $4.39. The company has a market cap of $448.17 million, a price-to-earnings ratio of -4.61 and a beta of -0.27.
enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, research analysts expect that enGene will post -1.56 earnings per share for the current fiscal year.
Institutional Trading of enGene
A number of large investors have recently bought and sold shares of the company. MAI Capital Management increased its position in enGene by 11.0% in the first quarter. MAI Capital Management now owns 78,067 shares of the company's stock worth $350,000 after buying an additional 7,756 shares during the last quarter. Cresset Asset Management LLC purchased a new stake in enGene in the second quarter worth $36,000. Paloma Partners Management Co purchased a new stake in enGene in the second quarter worth $38,000. ADAR1 Capital Management LLC purchased a new stake in enGene in the first quarter worth $107,000. Finally, Adage Capital Partners GP L.L.C. increased its position in enGene by 2.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock worth $7,041,000 after buying an additional 41,874 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.
About enGene
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
